Alprazolam, available under the trade name Xanax, is a potent, short-acting benzodiazepine anxiolytic—a minor tranquilizer. It is commonly used for the treatment of anxiety disorders, especially of panic disorder, but also in the treatment of generalized anxiety disorder (GAD) or social anxiety disorder. It was the 12th most prescribed medicine in the United States in 2010. Alprazolam, like other benzodiazepines, binds to specific sites on the GABAA receptor. It possesses anxiolytic, sedative, hypnotic, skeletal muscle relaxant, anticonvulsant, amnestic, and antidepressant properties. Alprazolam is available for oral administration as compressed tablets (CT) and extended-release capsules (XR).
Peak benefits achieved for generalized anxiety disorder (GAD) may take up to a week. Tolerance to the anxiolytic/antipanic effects is controversial, with only some authoritative sources supporting the development of tolerance; tolerance will, however, develop to the sedative-hypnotic effects within a couple of days. Withdrawal symptoms or rebound symptoms may occur after ceasing treatment abruptly following a few weeks or longer of steady dosing, and may necessitate a gradual dose reduction. Other risks include increased rates of suicide, possibly due to disinhibition.
Alprazolam was first released by Upjohn (now a part of Pfizer) in 1981.
The first approved use was of panic disorder, and within two years of
its original marketing, Xanax became a blockbuster drug in the US.
Presently, alprazolam is the most prescribed and the most misused benzodiazepine in the US.
The potential for misuse among those taking it for medical reasons is
controversial, with some expert reviews stating that the risk is low and
similar to that of other benzodiazepine drugs.
Others state that there is a substantial risk of misuse and dependence
in both patients and non-medical users and that the high affinity
binding, high potency, short elimination half-life, and rapid onset of action may increase the misuse potential of alprazolam.
Compared to the large number of prescriptions, relatively few
individuals increase their dose on their own initiative or engage in drug-seeking behavior.
XANAX TRI-SCORE BARS 2MG X 50 TABLETS
- Product Code: XANAX TRI-SCORE BARS 2MG X 50 TABLETS
- Availability: In Stock
- Ex Tax: $220.00